ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.2684G>A (p.Ser895Asn)

dbSNP: rs201864483
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 11
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000508371 SCV000603065 uncertain significance not specified 2017-03-09 criteria provided, single submitter clinical testing
Counsyl RCV000667642 SCV000792124 uncertain significance Cystic fibrosis 2017-06-09 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV001158765 SCV001320420 uncertain significance CFTR-related disorder 2017-04-28 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance.
ACT Genomics, RCV001265632 SCV001443776 likely benign Breast neoplasm 2020-11-06 criteria provided, single submitter clinical testing The allele frequency of this variant c.2684G>A (p.Ser895Asn) is 0.0026 in East Asian of gnomAD and 0.003 in East Asian in 1000 Genomes. The variant is predicted to be tolerated by both SIFT or PolyPhen2. For these reasons, this variant has been classified as Likely Benign.
Quest Diagnostics Nichols Institute San Juan Capistrano RCV001284478 SCV001470298 uncertain significance not provided 2020-07-09 criteria provided, single submitter clinical testing
Invitae RCV000667642 SCV001711087 likely benign Cystic fibrosis 2024-01-21 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000667642 SCV001822116 uncertain significance Cystic fibrosis 2021-07-22 criteria provided, single submitter clinical testing
Sema4, Sema4 RCV002257389 SCV002529701 uncertain significance Hereditary pancreatitis 2021-05-24 criteria provided, single submitter curation
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000508371 SCV002548052 benign not specified 2022-05-20 criteria provided, single submitter clinical testing Variant summary: CFTR c.2684G>A (p.Ser895Asn) results in a conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00035 in 251266 control chromosomes, predominantly at a frequency of 0.0048 within the East Asian subpopulation in the gnomAD database. The variant occurs with an even higher frequency in the Other East-Asian (presumably mostly Chinese) sub population (i.e. with a frequency of 0.006), and although this frequency is not higher than the estimated maximum expected for a pathogenic variant in CFTR causing Cystic Fibrosis (CF) in the Caucasian population (0.013), however, in a recent study the estimated Chinese CF prevalence was reported to be about 40x lower than the prevalence in Caucasians (Ni_2022), suggesting that the variant is a benign polymorphism found primarily in populations of East Asian origin. The variant, c.2684G>A, has been reported in the literature in four Chinese individuals affected with Cystic Fibrosis (Wu_2000, Alper_2003, Wang_2019, Yang_2021), however, in all of these patients the variant occurred in cis with a pathogenic variant (c.2083dupG (p.Glu695fs)), and all patients also carried a pathogenic variant (c.1898+5G>T) in trans, therefore these co-occurrences with other pathogenic variants provide supporting evidence for a benign role. The variant was also reported in two Chinese patients affected with congenital absence of vas deferens (CAVD; Luo_2021), however one of these patients also carried the variant c.2083dupG (p.Glu695fs) which was described earlier in cis in four Chinese CF patients, while the other patient carried two (potentially) pathogenic variants which could explain the phenotype (though the phase was not specified). In addition, the variant was published in heterozygous state in individuals affected with pancreatitis (Chang_2015, Palermo_2016) and bronchiectasis (Guan_2018), but was also found in healthy subject with a similar frequency (Guan_2018). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven submitters have provided clinical-significance assessments for this variant in ClinVar after 2014 without evidence for independent evaluation, and classified the variant as VUS (n=5) or likely benign (n=2). Based on the evidence outlined above, the variant was classified as benign.
Ambry Genetics RCV000667642 SCV002744722 likely benign Cystic fibrosis 2021-01-22 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
PreventionGenetics, part of Exact Sciences RCV001158765 SCV004114392 uncertain significance CFTR-related disorder 2023-05-30 criteria provided, single submitter clinical testing The CFTR c.2684G>A variant is predicted to result in the amino acid substitution p.Ser895Asn. This variant has been reported in patients with pancreatitis (Table 3, Palermo et al. 2016. PubMed ID: 27171515; Chang et al. 2007. PubMed ID: 17539902; Chang et al. 2015. PubMed ID: 25869325) and bronchiectasis (Guan et al. 2018. PubMed ID: 29997923). The patient discussed in Guan et al. was also homozygous for a different variant in CFTR. This variant is reported in 0.46% of alleles in individuals of East Asian descent in gnomAD ( Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.